Genetic profile and clinical implications of hepatoblastoma and neuroblastoma coexistence in a child by Skoczeń, Szymon et al.
CASE REPORT
published: 04 April 2019
doi: 10.3389/fonc.2019.00230
Frontiers in Oncology | www.frontiersin.org 1 April 2019 | Volume 9 | Article 230
Edited by:
Michael Eccles,
University of Otago, New Zealand
Reviewed by:
Pawel Buczkowicz,
Gene42, Inc., Canada
Ronald Przygodzki,
United States Department of
Veterans Affairs, United States
*Correspondence:
Konrad Stepien
konste@interia.eu
Specialty section:
This article was submitted to
Cancer Genetics,
a section of the journal
Frontiers in Oncology
Received: 11 January 2019
Accepted: 14 March 2019
Published: 04 April 2019
Citation:
Skoczen S, Stepien K, Krzysztofik M,
Luszawska T, Hnatko-Kolacz M,
Korostynski M, Piechota M,
Kolanek K, Wyrobek L, Wysocka K,
Gorecki W and Balwierz W (2019)
Genetic Profile and Clinical
Implications of Hepatoblastoma and
Neuroblastoma Coexistence in a
Child. Front. Oncol. 9:230.
doi: 10.3389/fonc.2019.00230
Genetic Profile and Clinical
Implications of Hepatoblastoma and
Neuroblastoma Coexistence in a
Child
Szymon Skoczen 1,2, Konrad Stepien 3*, Marta Krzysztofik 3, Teresa Luszawska 1,
Malgorzata Hnatko-Kolacz 1, Michal Korostynski 4,5, Marcin Piechota 4,5,
Katarzyna Kolanek 5, Lukasz Wyrobek 6, Katarzyna Wysocka 7, Wojciech Gorecki 8 and
Walentyna Balwierz 1,2
1Department of Oncology and Hematology, University Children’s Hospital, Krakow, Poland, 2Department of Pediatric
Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland, 3 Student
Scientific Group of Pediatric Oncology and Hematology, Jagiellonian University Medical College, Krakow, Poland,
4Department of Molecular Neuropharmacology, Institute of Pharmacology of Polish Academy of Sciences, Krakow, Poland,
5 Intelliseq sp. z o.o., Krakow, Poland, 6Department of Radiology, University Children’s Hospital, Krakow, Poland,
7Department of Pathology, University Children’s Hospital, Krakow, Poland, 8Department of Pediatric Surgery, Institute of
Pediatrics, Jagiellonian University Medical College, Krakow, Poland
The aim of the following case report is to provide a description of the coexistence of
two independent tumors in a child. A 9-month-old male was referred to Department
of Pediatric Oncology and Hematology with hepatic tumor present on ultrasound
imaging and symptoms of enlarged abdominal circumference. Physical examination
revealed a palpable epigastric mass and the imaging techniques showed a tumor
of the left hepatic lobe measuring 11 × 6.5 × 8.9 cm with pancreas infiltration,
distant metastases in both lungs and abnormal lesion in the left adrenal gland. Basing
on histopathological examination, after a core-needle biopsy, hepatoblastoma (HBL)
(mixed epithelial-mesenchymal subtype) was diagnosed. The α-fetoprotein level was
112 993 ng/ml. Elevated values of normetanephrine, 3-methoxytyramine as well as
neuron-specific enolase were observed. Due to the clinical picture and diagnosis,
the patient was qualified to preoperative chemotherapy according to the SIOPEL-3
protocol, followed by SIOPEL-4 protocol for the high-risk patients. After undergoing
preoperative chemotherapy, imaging tests revealed regression of hepatic tumor and no
focal pulmonary masses, while regression of adrenal glandmass was not completed. The
patient was qualified for left hemihepatectomy with left adrenalectomy. Histopathological
examination of liver specimen confirmed the HBL diagnosis. However, in left adrenal
gland and paraaortic lymph nodes the residual neuroblastoma (NBL) cells were detected.
Whole exome sequencing (WES) was utilized to identify disease-associated germline
mutations. WES revealed a novel germline insertion variant in TWIST1 (p.Gly86dup),
along with the potentially pathogenic non-synonymous variants in NF1 (p.Val2511Ile),
RAF1 (p.Leu445Arg), and WHSC1 (p.Ser4Asn) genes. Currently, 6 months after
completion of treatment according to the SIOPEL-4 protocol, the patient is in good
general condition, without any signs, and symptoms of relapse of both neoplasms. The
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coexistence of two different primary childhood malignancies is rarely seen. So far, only
one case of synchronous HBL and NBL has been reported. However, for the first time
therapeutic process was successful. A specific signature of rare germline mutations can
be proposed as a predisposing factor to synchronous HBL and NBL occurrence.
Keywords: malignant neoplasms, children, hepatoblastoma, neuroblastoma, mutation
INTRODUCTION
Sporadic or multifactorial etiology is considered as a cause
in most cases of cancer development in children. However,
as has been shown, up to 10% of cancer cases that occur in
children are related to known predisposing genetic syndromes
(1). For instance, Beckwith-Wiedemann syndrome, Familial
Adenomatous Polyposis, neurofibromatosis type 1 and Li-
Fraumeni syndrome are disorders with increased tumor risk. An
accurate molecular diagnosis gives a possibility to implement
appropriate primary prevention or to detect developing cancer
at an early stage by regular screening. In some cases, especially
in the absence of a significant family history and characteristic
dysmorphic features, the developing cancer disease may indicate
the undiagnosed genetic condition. According to data from the
literature, the type of diagnosed cancer accounts for 18% of the
reasons for referring the child to further genetic testing (2). High-
throughput methods such as next-generation sequencing (NGS)
allow for an accurate and comprehensive genetic analysis in a
relatively short time.
The presence of significant genetic disorders is extremely
suspected in the rare coexistence of two independent solid
tumors. Both hepatoblastoma (HBL), the most common primary
malignant neoplasm of the liver in children and neuroblastoma
(NBL), the most frequent extracranial solid tumor, belong to the
same group of tumors consisting of immature cells which often
resemble individual stages of embryonic organs development.
The incidence of HBL according to US registers is 1.6 cases per
million, while NBL−10.54 cases per million (3). Because of the
low occurrence rates, accidental simultaneous development of
two mentioned tumors in the same patient is very unlikely.
To our knowledge, in the available literature only one case
of the coexistence of HBL and NBL in a child has been already
described (4).
BACKGROUND
We report a case of a 9-month-old male referred to Department
of Pediatric Oncology and Hematology with suspicion of
hepatic tumor measuring 12.5 × 7 cm on ultrasound imaging.
His medical history was remarkable for enlarged abdominal
circumference lasting for 2 months, with no abdominal pain
or gastrointestinal disorders. Physical examination revealed an
extensive palpable epigastric mass. All kinds of dysmorphic
features were excluded.
Computed tomography (CT) imaging was performed as a part
of routine surveillance and showed: (1) tumor of the left hepatic
lobe measuring 11 × 6.5 × 8.9 cm, infiltrating pancreas and
adhering to falciform ligament of the liver, neck of gallbladder,
main trunk of portal vein, common hepatic artery and inferior
vena cava [PRETEXT III: V2, P1(2), E+, M+] (Figure 1A);
(2) hypodense abnormal lesion in the left adrenal gland with
calcifications and no contrast enhancement, measuring 2.3× 1.6
× 3.6 cm (Figure 1B); (3) enlarged left paraaortic lymph nodes
up to 1.4 cm with single calcifications; (4) distant peripheral and
subpleural metastatic lesions in both lungs.
A core-needle biopsy of segment IV and V of the liver
revealed HBL (mixed epithelial-mesenchymal subtype). The
initial α-fetoprotein (AFP) level was 112 993 ng/ml (age/sex-
adjusted reference ranges: 7–53 ng/ml). Patient presented no
viral hepatitis infections. Due to the presence of abnormal mass
in left adrenal gland, urinary excretion of catecholamines and
their metabolites as well as serum neuron-specific enolase (NSE)
levels were measured. Increased values of normetanephrine
(1.32 µg/mg creatinine, [0.27–1.11]), 3-methoxytyramine (1.31
µg/mg creatinine, [0.37–1.24]) and NSE [40.81 ng/ml, (4–20)]
were noted. Fluctuations of NSE in the perioperative period are
presented in Figure 2.
Due to the clinical picture and diagnosis, the patient
was qualified for preoperative chemotherapy according to the
SIOPEL-3 protocol (cisplatin, carboplatin, doxorubicin) (5).
Therapy was complicated by anemia requiring leukocyte-reduced
red blood cell transfusion. In the course of the treatment,
diminished abdominal circumference, and decrease of serum
AFP level to 24 465 ng/ml were observed. In 4th week of
chemotherapy CT imaging was performed and revealed reduced
tumor masses in liver (PRETEXT II: V1, E1), left adrenal gland
and lungs. Further treatment was continued according to the
SIOPEL-4 protocol (cisplatin, doxorubicin) (6). Anemia and
leukopenia requiring the subsequent leukoreduced transfusion as
well as bilateral symmetric high-frequency hearing loss detected
by the otoacoustic emissions method have occurred during
the therapy. Control CT performed after the completion of
preoperative chemotherapy showed a decrease in hepatic tumor
mass to 5.6 × 5.2 × 6.3 cm and a complete remission of focal
lesions in the lungs. However, there was no further reduction
of the hypodense lesion in the left adrenal gland (2.2 × 1.4 ×
2.5 cm). Gradual decrease in AFP concentration to 191.7 ng/ml
was also observed.
The patient was qualified for surgical treatment: left
hemihepatectomy and left adrenalectomy. Elective surgical
procedure was performed 4 months after the beginning of
oncological treatment. The histopathological examination of
the removed liver tumor confirmed the initial diagnosis of
HBL (mixed epithelial-mesenchymal subtype) (Figures 3A,B).
In turn, in the material from adrenal tumor residual remnants
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FIGURE 1 | Initial CT scans. (A) Hepatoblastoma of the left hepatic lobe measuring 11 × 6.5 × 8.9 cm. (B) Neuroblastoma of the left adrenal gland measuring 2.3 ×
1.6 × 3.6 cm.
of NBL (Schwannian stroma—poor, differentiating subtype)
(synaptophysin +, NSE +) were found in the regression stage
(Figures 3C,D). Calcifications with ambiguous single cells were
visualized also in the left paraaortic lymph nodes (synaptophysin
+/−, NSE +/−). Furthermore, analysis of the tumor material
with array comparative genomic hybridization (aCGH) showed
lack ofMYCN amplification.
In the early postoperative period, the bile leakage was
observed without the formation of fluid collections. In the next
days of hospitalization symptoms of transient gastrointestinal
obstruction resolved and parenteral nutrition was gradually
reduced. Wound healing proceeded properly.
Currently the patient is in good general condition, without any
signs and symptoms of relapse of both neoplasms, 6 months after
completion of treatment according to the SIOPEL-4 protocol for
HR Super PLADO.
GENETIC TESTING
Due to the clinical course of the disease and histopathologically
confirmed coexistence of two independent solid tumors, genetic
tests were carried out. Genomic DNA was extracted from the
peripheral blood samples according to the standard protocols.
Whole exome sequencing (WES) was performed on Illumina
HiSeq X Ten platform, using sequencing libraries generated with
Agilent SureSelect Human All Exon V6 Kit (60Mb target size,
covering 99% of exons regions from RefSeq, CCDS, HGMD_cds,
andOMIM_cds databases) and TruSeqDNALibrary Preparation
Kit. The raw reads from FASTQ files were aligned to hs38DH
reference genome using BWA MEM algorithm (version 0.7.15).
Resulting BAM files were post-processed with Sentieon software
implementing the equivalent GATK 3.5 Best Practices protocol
and the GVCFs files were generated.
FIGURE 2 | Variability of neuron-specific enolase (NSE) levels during and after
combined-modality therapy.
The personalized panel of genes was created based on
Human Phenotype Ontology (HPO) (version: April 13, 2017).
The panel consists of genes associated with the phenotype:
“HP:0003006 Neuroblastoma”; “HP:0002884 Hepatoblastoma”,
and “HP:0002664 Neoplasm” (646 genes total). In order to
calculate the coverage of obtained genes across samples, the
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FIGURE 3 | Histopathological images. (A) Hepatoblastoma, mixed epithelial-mesenchymal subtype: areas of embryonal epithelial type cells, primitive mesenchyme
and osteoid formation. HE, magnification 200x. (B) Hepatoblastoma, mixed epithelial-mesenchymal subtype: fetal epithelial type cells with focal extramedullary
hematopoesis and mesenchymal component represented by osteoid formation. HE, magnification 200x. (C) Neuroblastoma, Schwannian stroma—poor,
differentiating subtype: scant differentiating neuroblasts and neuropil in the background. HE, magnification 200x. (D) Neuroblastoma, Schwannian stroma—poor,
differentiating subtype: positive immunohistochemical reaction for synaptophysin in tumor cells cytoplasm and neuropil. Magnification 200x.
custom script was employed. SNVs (Single Nucleotide Variants)
and INDELs (short INsertions and DELetions) were discovered
via joint genotyping of GVCFs.
The resulting VCF was annotated and filtered using an
analysis of designed workflow. After discarding variants with
QUAL <30, remaining variants were annotated on variant
and gene level. The variant level annotations consisted of:
flags designating the presence of variant [Online Mendelian
Inheritance in Man (OMIM), PubMed or Human Gene
Mutation Database (HGMD) databases], names of diseases
associated with a given variant and their clinical significance
[ClinVar (version: April 4th, 2017) and MITOMAP (version:
January 19th, 2017) databases] and their frequencies in 1000
Genomes, ExAC, gnomAD, MITOMAP and local database.
Variants were also annotated with impact prediction scores,
such as SnpEff annotations (version: 4.3i, database version:
GRCh38.86), SIFT—deleteriousness score (version: February
2th, 2017), GERP and PhastCons—evolutionary conservation
scores. Variant-level filtering removed variants more frequent
than 1% in 1000 Genomes, ExAC, or MITOMAP populations
and variants with SnpEff impact LOW or MODIFIER. Gene-
level filtering retained variants located in genes present
in the panel. All variants that have passed filters defined
above were additionally inspected using Integrative Genomics
Viewer (IGV) to detect and exclude from further analysis
false-positive calls.
Among genes associated in HPO database with autosomal
dominant model of disease inheritance, there were 4 potentially
pathogenic variants identified. The rare non-synonymous
variants in RAF1 (p.Leu445Arg) and WHSC1 (p.Ser4Asn) were
found. Both mutations have high SIFT deleteriousness score
(<0.11) and high evolutionary conservation (GERP >4.7 and
PhastCons = 1). A novel insertion variant in neoplasm-related
gene TWIST1 (p.Gly86dup) was identified, however, insertion
did not produce a translational frameshift and occurred in
the poorly evolutionary conserved region. There were also two
variants in neoplasm-related NF1 gene, including ultra-rare
non-synonymous variant (p.Val2511Ile) in a highly conserved
region (GERP > 4.0 and PhastCons = 1) though with poor
SIFT score (0.552) and synonymous likely benign variant
(p.Lys1745=). WES also detected known pathogenic variant in
MYOC (p.Gln368∗). The mutation was reported in ClinVar as
pathogenic with autosomal dominant inheritance for primary
open angle glaucoma. The obtained results of the analysis are
presented in abbreviated form in Table 1.
DISCUSSION
The above case report concerns a very rare clinical situation in
pediatric oncology. To date, few cases of coexistence of various
neoplasms in children have been described in the literature.
Detailed statistical data defining the actual frequency of this
phenomenon are missing. Due to the very low prevalence, there
are no original papers about specific treatment strategies. The
sequence of treatment and further outcomes depend on the
type of coexisting tumors and their aggressiveness. It is also
worth emphasizing that due to the similar and often nonspecific
symptoms of neoplastic disease in the pediatric population,
synchronous tumors constitute a diagnostic problem even for an
experienced physician.
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TABLE 1 | Selected potentially significant pathogenic genetic variants detected in the patient.
Gene
symbol
Position of
sequence
change
Variant
parameters
Inheritance pattern Classification Selected diseases
associated with the gene
NF1 p.Val2511Ile SIFT = 0.552
PhastCons = 1
GERP = 4.08
Autosomal dominant,
somatic mutation
Potentially significant variant
from dedicated panel
Neurofibromatosis type 1,
juvenile myelomonocytic
leukemia, Noonan
syndrome
RAF1 p.Leu445Arg SIFT = 0.098
PhastCons = 1
GERP = 4.71
Autosomal dominant Potentially significant variant
from dedicated panel
Neuroblastoma
TWIST1 p.Gly86dup PhastCons = 0
GERP = −0.67
Autosomal dominant Potentially significant variant
from dedicated panel
craniosynostosis 1,
craniosynostosis
syndrome, Robinow
Sorauf syndrome,
Sweeney-Cox
syndrome,
Saethre-Chotzen
syndrome
WHSC1 p.Ser4Asn SIFT = 0.041
PhastCons = 1
GERP = 4.74
Autosomal dominant,
sporadic mutation
Potentially significant variant
from dedicated panel
4p partial monosomy
syndrome
MYOC p.Gln368*
PhastCons = 1
GERP = 4.52
Autosomal dominant Known pathogenic variant
beside dedicated panel
Primary open angle
Glaucoma, primary
Open angle glaucoma
Juvenile onset 1
As mentioned above, only one case of the coexistence of
HBL and NBL in a child has been already described (4). In
both cases, the patients are infants and symptoms of the disease
resulted from locally advanced HBL. However, there are some
differences between the previously published case and the one
being described in this report. In the previously reported case,
multiple cutaneous capillary hemangiomas were found. In our
patient, the presence of other tumors was excluded on the basis
of a comprehensive physical examination and imaging tests.
Furthermore, the patient presented in the current report was
conceived naturally, while the previously described patient was
born following an in vitro fertilization-assisted pregnancy. The
treatment outcomes of both patients are also different. The infant
described by Ozawa et al. died immediately after admission due
to a ruptured liver which was caused by the developing HBL. In
turn, our patient despite of the advanced initial stage of disease
is 6 months after completion of treatment and remains in close
follow-up. In both cases different genetic techniques were used
and various results of the analyzes were also obtained. Ozawa
et al. performed their testing on the material from the twin
brother of the deceased patient and showed only Gaucher disease
carrier. In our case, an advanced WES was carried out using
NGS technology from material taken directly from the patient.
Numerous potentially significant pathogenic variants were found
(Table 1). However, there is a lack of genetic variants previously
associated with Gaucher disease.
One of the main diagnostic problems in the our case was
to determine the nature of the lesion in the left adrenal gland.
The adrenal glands are one of the possible locations of distant
metastases in HBL (7). This was indicated by the metastatic
phase of the disease—the presence of multiple lesions in both
lungs. However, several features typical for NBL, which suggested
the presence of a second independent tumor already at the
diagnostic stage may be noticed. The initial CT scan showed
the presence of hypodense lesion with calcifications and no
contrast enhancement. Numerous calcifications of adrenal gland
tumor could suggest the diagnosis of NBL—they are present
in about 79% of cases (8). The increase in their quantity
was also documented at the time of tumor regression during
chemotherapy (9). In most cases NBL manifests as a large
heterogeneous tumor with focal necrosis or hemorrhage but
small and accidentally discovered lesions may be homogeneous
(10). The lack of a contrast enhancement is another feature that
supports the diagnosis of NBL (11).
In our patient we also found the elevated values of
normetanephrine and 3-methoxytyramine. The increase in the
concentration of these methylated catecholamine metabolites is
observed in most patients with NBL (12). An important issue
was also the elevated NSE values in the perioperative period
(Figure 2). NSE is a diagnostic marker in patients with NBL and
its concentrations correlate with the stage of the disease (13).
Due to the local advancement and the presence of distant
metastases, HBL was considered the main therapeutic target
in the presented case. A satisfactory clinical, radiological
and enzymatic response was observed during preoperative
chemotherapy with SIOPEL-3 and SIOPEL-4 protocols dedicated
to high and very high risk patients (5, 6). A simultaneous initial
response of the NBL tumor and its subsequent stabilization were
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found. Two probable explanations for that situation may be
proposed. First of all, NBL cells are sensitive to drugs used in HBL
protocols—platinum derivatives and anthracyclines. They are
present in chemotherapy regimens used in NBL treatment (14,
15). Secondly, the unique and frequently observed spontaneous
regression among patients with NBL below 1 year of age cannot
be excluded. This is also supported by the lack of MYCN
amplification in our patient (16).
In the vast majority both tumors that occurred in our patient
are sporadic. Genetic syndromes are associated with 15% of
HBL while familial NBL occurs only in <5% of cases (17, 18).
Several syndromes have been recognized as being associated with
HBL and NBL. In our patient, whole-exome sequencing was
carried out and revealed numerous cancer-predisposing genes.
Mutations in NF1, RAF1, TWIST1, andWHSC1 genes have been
considered as cancer-related, therefore we decided to discuss
their potential impact on patient’s disease.
NF1 (OMIM 613113) mutation in patients with NBL is a
rare occurrence and, to our knowledge, has not been reported
previously in children with HBL. Martinsson et al. (19) gave
the first evidence of homozygous NF1 deletion in NBL and
suggested the role of NF1 inactivation in the development or
progression of this type of tumors. Origone et al. (20) reported
MYCN amplification and chromosome 1p36 deletion in patient
with NF1 amplification and NBL. In presented case, an ultra-
rare germline heterozygous missense mutation (p.Val2511Ile) in
a highly conserved region (GERP >4.0 and PhastCons = 1)
related with tumor predisposition has been reported.
NBL has been associated with several dominant disorders
caused by germline mutations in RAS signaling pathway,
involved in carcinogenesis. Noonan syndrome and LEOPARD
syndrome (known as Noonan syndromewithmultiple lentigines)
are both related with germline RAF1mutations (OMIM 164760)
and have been associated with increased risk of developing NBL
(21). In our patient, potentially pathogenic non-synonymous
variant inRAF1 gene (p.Leu445Arg), not yet previously described
in cancer-related conditions, has been found.
Of note, we revealed a novel germline insertion variant
in TWIST1 gene (p.Gly86dup) in patient with synchronous
NBL and HBL. To date, TWIST1 (OMIM 601622) has been
associated with craniosynostosis 1, Robinow-Sorauf syndrome
and Sweeney-Cox syndrome. The impact of TWIST1 mutations
on NBL has been rarely reported and remains unclear. Selmi
et al. (22) showed upregulated TWIST1 expression in MYCN
amplified NBL cells. Additionally, in vitro studies found TWIST1
to be a key regulator of the MYCN enhancer axis and a
collaboration between TWIST1 andMYCN may play role in NBL
development (23).
NBL in a child with Wolf-Hirschhorn syndrome, caused by
mutation in WHSC1 gene (OMIM 602952), is a rare occurrence
with only one case available in the medical literature (24). Our
patient presented a potentially pathogenic mutation in WHSC1
(p.Ser4Asn) gene with high SIFT deleteriousness score (<0.11)
and high evolutionary conservation (GERP >4.7 and PhastCons
= 1).
WES also detected known pathogenic variant in MYOC
(p.Gln368∗) reported as pathogenic with autosomal dominant
inheritance for primary open angle glaucoma.
The issue of follow-up and prognosis in this type of
patients remains unresolved. Complex genetic background
has already led to the development of two independent
tumors in the infancy. Undoubtedly, such unique genetic
disorders may predispose to the further neoplasms in the
future (25). In addition, the applied aggressive oncological
treatment may also cause secondary cancers. Furthermore,
extended genetic testing should also be carried out among the
family members.
CONCLUDING REMARKS
The coexistence of HBL and NBL represents extremely rare
clinical issue in pediatric oncology. To our knowledge, presented
case report is the second such description in the literature. The
use of combined oncological treatment in our patient led to
remission of both independent tumors. Based on performed
testing, a specific signature of rare germline mutations can be
proposed as a novel predisposing factor to synchronous HBL and
NBL occurrence.
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